U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967480) titled 'Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis' on May 05.
Brief Summary: The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Study Start Date: June 13
Study Type: OBSERVATIONAL
Condition:
Generalized Myasthenia Gravis
Anti-AChR Antibody Positive
Intervention:
DRUG: Ravulizumab
Participants will receive Ravulizumab.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Alexion Pharmaceuticals, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....